What is NERV's current stock price?

NERV (Minerva Neurosciences, Inc.) is currently trading at $5.26 with a market cap of $36.8M.

What sector is Minerva Neurosciences, Inc. in?

Minerva Neurosciences, Inc. (NERV) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is NERV a good stock to buy?

Analysts have a Hold consensus on NERV with a price target of $5.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

NERV Minerva Neurosciences, Inc.

Healthcare

$5.26-0.75%ClosedMarket Cap: $36.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-0.91

P/S

0.00

EV/EBITDA

-0.23

DCF Value

$1.98

FCF Yield

-14779.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

359.8%

ROA

-441.4%

ROIC

-31.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-125.4M	$—
Q4 null	$0.00	$-283.7M	$—
FY null	$0.00	$-293.4M	$—
Q3 null	$0.00	$-2.7M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$5.00

Target (Median)

$5.00

Target Range

$5.00 - $5.00

1 Strong Buy0 Buy2 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Neutral

2026-03-12

HC Wainwright & Co.Neutral

2025-11-06

Trading Activity

Insider Trades

View All

O'Connor James Josephofficer: Chief Business Officer and GC

SellWed Apr 22

O'Connor James Joseph

SellWed Apr 22

Kaul Inderjitdirector

SellWed Apr 01

VAN HEEK G JANdirector

SellTue Dec 23

Race Geoffofficer: President

SellTue Dec 23

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.10

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Peers